Nigeria: Xechem Invests $15 Million On Sickle Cell Drug
 |
 |
|||||||||
|
||||||||||
|
|
|||||||||
|
||||||||||
Vanguard (Lagos)
12 December 2007
Posted to the web 12 December 2007
Emma Ujah
Xechem Pharmaceutical Nigeria Limited disclosed at the weekend that it has invested over $15 million in the production of NICOSAN the world's most effective drug, yet, for the management of Sickle Cell Disease (SCD).Briefing the press in Abuja , the Managing Director (MD) of the company, Mr. Iretiolu Oniyide said the efforts of the company's board, management and staff had brought an unprecedented relief to SCD patients who could now live normal lives, without the usual crisis, once placed on the drug which is produced in Abuja .
"There has not been any drug for SCD that could bring relief and make patients live normal lives until the NICOSAN came on the stage. Now we have testimonies of users of the drug across the country who now live normal lives.
"We now have SCD patients who can go about their economic activities without crisis, children with sickle cell can now live normal lives, go to school, without being kept out of school by crisis. We are overwhelmed by the volume of testimonies of users and we are proud to be part of this great discovery', the MD said.
Mr. Oniyide, revealed that there were enemies of Nigeria who were hell bent on rubbishing the success story of NICOSAN but that he team at Xechem was prepared not only to refuse to be distracted but move ahead to expand its production lines and by so doing, make NICOSAN available to more SCD patients within and outside the country.
Relevant Links
He debunked a recent reports alleging the inefficacy of NICOSAN in the management of SCD and that the drug has not met the required quality control standards, stressing that NAFDAC, the apex regulatory authority has endorsed the drug as having passed through necessary quality control standards and processes.
Read comments. Write your own.
|
AllAfrica aggregates and indexes content from over 125 African news organizations, plus more than 200 other sources, who are responsible for their own reporting and views. Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
|
Copyright © 2007 Vanguard. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections -- or for permission to republish or make other authorized use of this material, click here.
| |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
|
Make allAfrica.com your home page
|
RSS Feed
Sign up for FREE daily 'top headlines' by email >> | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
| Top | Site Guide | Who We Are | Advertising | Search | My Account | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
| Questions or Comments? Contact us. Read our Privacy Statement. | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
